Takeda unit urges Fed Circ to revive antibody patent

Baxalta, a subsidiary of Japan-headquartered pharmaceutical company Takeda, has asked the US Court of Appeals for the Federal Circuit to overturn a decision that invalidated its antibody patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

US firm boosts patent bench with Desmarais hire

18 March 2026 A new partner hire at the firm brings rare depth across both the ITC and district courts in technology and life sciences.

Americas

J&J unit targets former employee over alleged mass data theft

17 March 2026 Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.

Careers

HSF Kramer hires patent litigator as partner in Germany

17 March 2026 New recruit, who has worked on more than 150 infringement cases, will join the firm’s disputes practice in Düsseldorf and strengthen its UPC offering.

More features

US firm boosts patent bench with Desmarais hire

J&J unit targets former employee over alleged mass data theft

HSF Kramer hires patent litigator as partner in Germany

INTA: ‘New normal’ for in-house counsel as budgets fall

Mylan withdraws defence claims against Novo in Wegovy dispute

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Astellas blocks generic version of key urology drug until 2030

Orrick adds specialist licensing partner in Silicon Valley

Takeda unit urges Fed Circ to revive antibody patent

More on this story

Editor's picks

Editor's picks

More features